IS6398A - Lyfjablöndur - Google Patents

Lyfjablöndur

Info

Publication number
IS6398A
IS6398A IS6398A IS6398A IS6398A IS 6398 A IS6398 A IS 6398A IS 6398 A IS6398 A IS 6398A IS 6398 A IS6398 A IS 6398A IS 6398 A IS6398 A IS 6398A
Authority
IS
Iceland
Prior art keywords
formulations
Prior art date
Application number
IS6398A
Other languages
English (en)
Other versions
IS2841B (is
Inventor
Dixon John
Humphries Robert
Jarvis Gavin
Kirk Ian
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS6398A publication Critical patent/IS6398A/is
Publication of IS2841B publication Critical patent/IS2841B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS6398A 1999-12-01 2002-05-27 Samstæða hluta og lyfjasamsetningar IS2841B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9904377A SE9904377D0 (sv) 1999-12-01 1999-12-01 Pharmaceutical combinations
PCT/SE2000/002378 WO2001039781A1 (en) 1999-12-01 2000-11-29 Pharmaceutical combinations

Publications (2)

Publication Number Publication Date
IS6398A true IS6398A (is) 2002-05-27
IS2841B IS2841B (is) 2013-08-15

Family

ID=20417947

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6398A IS2841B (is) 1999-12-01 2002-05-27 Samstæða hluta og lyfjasamsetningar

Country Status (32)

Country Link
US (2) US20030032618A1 (is)
EP (2) EP1237559B1 (is)
JP (1) JP2003515565A (is)
KR (1) KR100785953B1 (is)
CN (1) CN1402639A (is)
AR (1) AR033658A1 (is)
AT (1) ATE332698T1 (is)
AU (1) AU781691B2 (is)
BR (1) BR0016043A (is)
CA (1) CA2391161C (is)
CO (1) CO5271717A1 (is)
CY (1) CY1105211T1 (is)
CZ (1) CZ300925B6 (is)
DE (1) DE60029340T2 (is)
DK (1) DK1237559T3 (is)
EE (1) EE05127B1 (is)
ES (1) ES2267591T3 (is)
HU (1) HU230890B1 (is)
IL (1) IL149495A0 (is)
IS (1) IS2841B (is)
MX (1) MXPA02004871A (is)
MY (1) MY128896A (is)
NO (1) NO331215B1 (is)
NZ (2) NZ530058A (is)
PT (1) PT1237559E (is)
RU (1) RU2242232C2 (is)
SE (1) SE9904377D0 (is)
SI (1) SI1237559T1 (is)
SK (1) SK288707B6 (is)
TW (1) TWI251491B (is)
WO (1) WO2001039781A1 (is)
ZA (1) ZA200203707B (is)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US6897201B2 (en) 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
DE10064797A1 (de) * 2000-12-22 2002-06-27 Knoll Ag Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
EP1604669A1 (en) * 2004-06-10 2005-12-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of ATP analogues for treatment of cardiovascular diseases
CN101253179B (zh) * 2005-09-21 2010-12-29 株式会社钟根堂 S-氯吡格雷的树脂酸盐复合物及其制备方法
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
BR112012011298B1 (pt) * 2009-11-11 2021-12-14 Chiesi Farmaceutici S.P.A. Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2012109406A1 (en) 2011-02-09 2012-08-16 The Medicines Company Methods for treating pulmonary hypertension
AU2013381855B2 (en) 2013-03-09 2018-08-02 Chiesi Farmaceutici S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2018234565A1 (en) 2017-06-23 2018-12-27 Chiesi Farmaceutici S.P.A. METHOD FOR PREVENTING SHUNT THROMBOSIS FROM THE SYSTEMIC-PULMONARY ARTERY

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8826448D0 (en) * 1988-11-11 1988-12-14 Thrombosis Res Inst Improvements in/relating to organic compounds
DE69204717T2 (de) * 1991-04-06 1996-04-25 Astra Pharmaceuticals Limited, Kings Langley, Herts ATP-Analogen.
SK281309B6 (sk) * 1993-02-10 2001-02-12 Astra Pharmaceuticals Limited N-alkyl-2-substituované adenozíntrifosfátové deriváty, spôsob ich prípravy, farmaceutické prostriedky obsahujúce tieto deriváty a použitie týchto derivátov
IL110040A (en) * 1993-06-29 2000-07-16 Nissan Chemical Ind Ltd Pyridazinone derivatives their preparation and pharmaceutical compositions comprising them
MA23420A1 (fr) * 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
DE19515500A1 (de) * 1995-04-27 1996-10-31 Thomae Gmbh Dr K Substituierte Phenylamidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
HU221880B1 (hu) * 1995-07-11 2003-02-28 Astrazeneca Ab, Vérlemezke-aggregáció inhibitorok, ezeket tartalmazó gyógyszerkészítmények és előállításuk
WO1999065500A1 (en) * 1998-06-17 1999-12-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US6462021B1 (en) * 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
US6696468B2 (en) * 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
AU2003270861A1 (en) * 2002-10-02 2004-04-23 Bristol-Myers Squibb Company Novel combination of a factor xa inhibitor and clopidogrel
JPWO2005007191A1 (ja) * 2003-07-16 2006-08-31 協和醗酵工業株式会社 医薬組成物

Also Published As

Publication number Publication date
JP2003515565A (ja) 2003-05-07
CZ300925B6 (cs) 2009-09-09
NO20022606L (no) 2002-07-11
AU781691B2 (en) 2005-06-09
KR100785953B1 (ko) 2007-12-14
TWI251491B (en) 2006-03-21
RU2002117296A (ru) 2004-01-20
NO20022606D0 (no) 2002-05-31
SK7502002A3 (en) 2003-02-04
ZA200203707B (en) 2003-10-29
NO331215B1 (no) 2011-11-07
CZ20021887A3 (cs) 2002-11-13
NZ530058A (en) 2005-04-29
ATE332698T1 (de) 2006-08-15
AR033658A1 (es) 2004-01-07
EP1719526A3 (en) 2007-04-25
SE9904377D0 (sv) 1999-12-01
IL149495A0 (en) 2004-03-28
MXPA02004871A (es) 2002-08-30
MY128896A (en) 2007-02-28
DE60029340T2 (de) 2007-07-19
BR0016043A (pt) 2002-07-23
CO5271717A1 (es) 2003-04-30
AU1910901A (en) 2001-06-12
EE200200271A (et) 2003-06-16
HUP0203585A2 (hu) 2003-03-28
NZ518904A (en) 2004-02-27
CA2391161C (en) 2010-10-05
DK1237559T3 (da) 2006-10-30
WO2001039781A1 (en) 2001-06-07
EE05127B1 (et) 2009-02-16
EP1237559A1 (en) 2002-09-11
DE60029340D1 (de) 2006-08-24
HK1047893A1 (en) 2003-03-14
PL355841A1 (en) 2004-05-17
EP1237559B1 (en) 2006-07-12
ES2267591T3 (es) 2007-03-16
KR20020069201A (ko) 2002-08-29
HUP0203585A3 (en) 2005-01-28
US20030032618A1 (en) 2003-02-13
SK288707B6 (sk) 2019-10-02
EP1719526A2 (en) 2006-11-08
US20060270607A1 (en) 2006-11-30
CN1402639A (zh) 2003-03-12
CY1105211T1 (el) 2010-03-03
HU230890B1 (hu) 2018-12-28
PT1237559E (pt) 2006-10-31
IS2841B (is) 2013-08-15
CA2391161A1 (en) 2001-06-07
SI1237559T1 (sl) 2007-02-28
RU2242232C2 (ru) 2004-12-20

Similar Documents

Publication Publication Date Title
IS5555A (is) Selekoxib lyfjablöndur
ID30031A (id) Formulasi-formulasi agrokimia
ID23546A (id) Formulasi-formulasi ziprasidon
NO20004240D0 (no) Formuleringer
ATE224703T1 (de) Brauseformulierungen
NO2010019I2 (no) 6-per-deoksy-6-per-(2-karboksetyl)tio-y-cyklodextrin
DE60011764D1 (de) Werkstoffsprüfung
DE60020629D1 (de) Kassettengleitringdichtung
PT1130966E (pt) Formulacoes antiparasitarias
DE69932949D1 (de) Aufszugssteuerung
DE60002808D1 (de) Propellerrotornabe
DE60016396D1 (de) Foerdervorrichtung
ATE259590T1 (de) Pour-on formulierungen
EE200200150A (et) Preparaat
DK1190020T3 (da) Celluligninbrændstof
DE60001894D1 (de) Busschienenverbindungsstruktur
DE50009570D1 (de) Wechselcorrugator
DE59909346D1 (de) Zylinderkopfdichtung
DE69924240D1 (de) Ladungsträgerteilchenstrahlvorrichtung
DE60025623D1 (de) Bohrmeisselverbinder
DE60034087D1 (de) Farbeditiersystem
ATE268116T1 (de) Mesotrion-formulierungen
DE60013238D1 (de) Klingenabstreifanordnung
DE50012482D1 (de) Tibiamarknagel
DE50003660D1 (de) Diacylhydrazinderivate